Astrazeneca Phar

Who are the top shareholders of the Astrazeneca Phar?

The top shareholders of Astrazeneca Phar include Astrazeneca Pharmaceuticals Ab with 75.0%, Nippon Life India Trustee Ltd at 2.92%, mutual funds holding 4.45%, foreign institutional investors at 2.89%, and individual investors with 15.16%.

The top shareholders of Astrazeneca Phar include Astrazeneca Pharmaceuticals Ab, which holds a significant 75.0% of the shares. Other notable shareholders are Nippon Life India Trustee Ltd, representing the Nippon India Small Cap Fund across various schemes, with a holding of 2.92%. Additionally, mutual funds collectively hold 4.45% through 53 schemes, and foreign institutional investors (FIIs) own 2.89% across 95 entities. Individual investors also have a notable presence, holding 15.16% of the shares.

Who are in the management team of Astrazeneca Phar?

As of March 2023, the management team of Astrazeneca Phar includes Narayan K Seshadri (Chairman), Rajesh Marwaha (CFO), Sanjeev Panchal (Managing Director), and several non-executive and independent directors. Key members also include Revathy Ashok, Weiying Sarah Wang, Ankush Nandra, Shilpa Divekar Nirula, and Hooi Bien Chuah.

As of March 2023, the management team of Astrazeneca Phar includes the following members:<BR><BR>1. Narayan K Seshadri - Chairman & Independent Director<BR>2. Revathy Ashok - Non-Executive & Independent Director<BR>3. Rajesh Marwaha - Whole Time Director & CFO<BR>4. Weiying Sarah Wang - Non-Executive Director<BR>5. Ankush Nandra - Non-Executive Director<BR>6. Shilpa Divekar Nirula - Non-Executive & Independent Director<BR>7. Sanjeev Panchal - Managing Director<BR>8. Hooi Bien Chuah - Non-Executive Director<BR><BR>These individuals play key roles in the governance and management of the company.

When is the next results date for Astrazeneca Phar?

No Upcoming Board Meetings

Has Astrazeneca Phar declared dividend?

Astrazeneca Pharma India Ltd has declared a 1200% dividend, amounting to ₹24 per share, with an ex-date of July 5, 2024. The company has shown strong price appreciation over various periods, with total returns of up to 233.77% over three years, despite low dividend yields.

Astrazeneca Pharma India Ltd has declared a 1200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1200%<BR>- Amount per share: 24<BR>- Ex-date: 05 Jul 24<BR><BR>Dividend Yield: 0.24%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 48.19%, with a dividend return of 0%, resulting in a total return of 48.19%.<BR><BR>Over the past year, the price return was 58.09%, with a dividend return of 0.38%, leading to a total return of 58.47%.<BR><BR>In the 2-year period, the price return was 181.37%, with a dividend return of 1.10%, culminating in a total return of 182.47%.<BR><BR>For the 3-year period, the price return was 232.0%, with a dividend return of 1.77%, resulting in a total return of 233.77%.<BR><BR>In the last 4 years, the price return was 158.33%, with a dividend return of 1.37%, leading to a total return of 159.7%.<BR><BR>Over the past 5 years, the price return was 208.87%, with a dividend return of 1.47%, culminating in a total return of 210.34%.<BR><BR>Overall, Astrazeneca Pharma India Ltd has declared a significant dividend, and the total returns across various periods indicate strong price appreciation, particularly over longer time frames, despite relatively low dividend returns in the short term.

Who are the peers of the Astrazeneca Phar?

Astrazeneca Phar's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Biotech, Jubilant Pharmo, Caplin Point Lab, Natco Pharma, and Sai Life. Astrazeneca Phar has a 1-year return of 52.64%, with peers like Jubilant Pharmo showing the highest return at 69.21%.

Peers: The peers of Astrazeneca Phar are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Biotech, Jubilant Pharmo, Caplin Point Lab, Natco Pharma, and Sai Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Astrazeneca Phar, Caplin Point Lab, Natco Pharma, and the rest. Below Average growth is noted for Divi's Lab., Torrent Pharma, Astrazeneca Phar, Jubilant Pharmo, and the rest, while Excellent growth is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Astrazeneca Phar, Concord Biotech, Caplin Point Lab, Natco Pharma, and the rest, while Average capital structure is found at Jubilant Pharmo.<BR><BR>Return Snapshot: Jubilant Pharmo has the highest 1-year return at 69.21%, while Natco Pharma has the lowest at -13.51%. Astrazeneca Phar's 1-year return is 52.64%, which is significantly higher than Natco Pharma's but lower than Jubilant Pharmo's. Additionally, the peers with negative six-month returns include Concord Biotech, Natco Pharma, and Jubilant Pharmo.

Is Astrazeneca Phar overvalued or undervalued?

As of March 31, 2020, Astrazeneca Phar is considered very expensive with a PE ratio of 120.70, significantly higher than peers like Sun Pharma and Divi's Lab, indicating overvaluation despite strong stock performance.

As of 31 March 2020, Astrazeneca Phar's valuation grade moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued, with a PE ratio of 120.70, an EV to EBITDA ratio of 94.10, and a PEG ratio of 3.45. These ratios highlight a premium valuation compared to its peers, such as Sun Pharma, which has a PE ratio of 35.25, and Divi's Lab, with a PE ratio of 79.33.<BR><BR>The peer comparison further emphasizes Astrazeneca Phar's elevated valuation, as it stands out with its very expensive classification against a backdrop of peers that are either expensive or attractive. Additionally, the company's strong performance in stock returns, significantly outpacing the Sensex over various timeframes, reinforces the notion of overvaluation, as investors may be pricing in future growth that may not be sustainable at current levels.

What does Astrazeneca Phar do?

AstraZeneca Pharma India Limited manufactures, distributes, and markets pharmaceutical products, reporting net sales of ₹4,805 Cr and a net profit of ₹582 Cr for the quarter ending March 2025. It has a market cap of ₹23,391 Cr and key metrics include a P/E ratio of 114.00 and a return on equity of 28.39%.

Overview: <BR>AstraZeneca Pharma India Limited is engaged in the manufacture, distribution, and marketing of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and is categorized as a Large Cap company.<BR><BR>History: <BR>AstraZeneca Pharma India Ltd was incorporated on July 11, 1979. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 4,805 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 582 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 23,391 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 114.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.70 <BR>Return on Equity: 28.39% <BR>Price to Book: 32.23<BR><BR>Contact Details: <BR>Address: Blk N1 12th Flr Manyata Embass, Rachenahalli Outer Ring Road Bangalore Karnataka : 560045 <BR>Tel: 91-080-67748000 <BR>Email: comp.secy@astrazeneca.com <BR>Website: http://www.astrazeneca.in

How big is Astrazeneca Phar?

As of 24th July, Astrazeneca Pharma India Ltd has a market capitalization of 22,450.00 Cr, with recent net sales of 1,716.29 Cr and a net profit of 115.74 Cr.

As of 24th July, Astrazeneca Pharma India Ltd has a market capitalization of 22,450.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,716.29 Cr and a Net Profit of 115.74 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 711.92 Cr and Total Assets of 1,056.78 Cr.

How has been the historical performance of Astrazeneca Phar?

Astrazeneca Phar has shown significant growth in net sales, reaching 1,716.29 Cr in March 2025, up from 1,002.97 Cr in March 2023, despite a decline in profit margins and earnings per share. Total assets and liabilities increased to 1,476.56 Cr, while cash and cash equivalents rose to 536.70 Cr, indicating improved cash flow.

Answer:<BR>The historical performance of Astrazeneca Phar shows a significant growth trend in net sales and profits over the years, with net sales reaching 1,716.29 Cr in March 2025, up from 1,295.53 Cr in March 2024 and 1,002.97 Cr in March 2023. The total operating income followed a similar trajectory, increasing to 1,716.29 Cr in March 2025 from 1,295.53 Cr in March 2024. However, total expenditure also rose to 1,462.32 Cr in March 2025, compared to 1,111.08 Cr in March 2024, leading to an operating profit of 294.60 Cr in March 2025, up from 219.25 Cr in March 2024. Profit before tax decreased to 156.36 Cr in March 2025 from 219.54 Cr in March 2024, while profit after tax was 115.74 Cr in March 2025, down from 161.51 Cr in March 2024. The earnings per share (EPS) also saw a decline to 46.3 in March 2025 from 64.6 in March 2024. <BR><BR>In terms of assets and liabilities, total assets increased to 1,476.56 Cr in March 2025 from 1,056.78 Cr in March 2024, while total liabilities also rose to 1,476.56 Cr in March 2025 from 1,056.78 Cr in March 2024. The company maintained a strong cash position, with cash and cash equivalents rising to 536.70 Cr in March 2025 from 505.84 Cr in March 2024. The net cash inflow for March 2025 was 30.00 Cr, compared to 5.00 Cr in March 2024, indicating improved cash flow from operations. Overall, Astrazeneca Phar has demonstrated robust growth in sales and assets, despite fluctuations in profit margins and earnings per share.<BR><BR>Breakdown:<BR>Astrazeneca Phar has shown a strong upward trend in net sales, which increased from 1,002.97 Cr in March 2023 to 1,716.29 Cr in March 2025. This growth in revenue has been accompanied by a rise in total operating income, which reached 1,716.29 Cr in March 2025. However, the total expenditure also increased significantly, leading to an operating profit of 294.60 Cr in March 2025, a rise from 219.25 Cr in March 2024. Despite this, profit before tax saw a decline to 156.36 Cr in March 2025, down from 219.54 Cr in the previous year, and profit after tax also decreased to 115.74 Cr. The earnings per share reflected this trend, dropping to 46.3 in March 2025 from 64.6 in March 2024. On the balance sheet, total assets grew to 1,476.56 Cr in March 2025, while total liabilities matched this figure, indicating a balanced growth in both assets and liabilities. The company maintained a healthy cash position, with cash and cash equivalents increasing to 536.70 Cr, and a net cash inflow of 30.00 Cr in March 2025 suggests improved operational cash flow.

Is Astrazeneca Phar technically bullish or bearish?

As of November 7, 2025, the trend is mildly bullish, supported by positive MACD readings and moving averages, despite mixed signals from the KST and recent price declines, with strong long-term returns over 3 and 5 years.

As of 7 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by weekly and monthly MACD readings indicating bullish momentum. The Bollinger Bands and moving averages also reflect a mildly bullish outlook on the daily time frame. However, the KST shows a mixed signal with a bullish weekly but mildly bearish monthly reading. The Dow Theory aligns with a mildly bullish stance on both weekly and monthly charts. Despite recent price declines, the longer-term returns remain strong, particularly over 3 years and 5 years, indicating resilience in the stock.

Are Astrazeneca Pharma India Ltd latest results good or bad?

AstraZeneca Pharma India Ltd's latest Q3 FY26 results show strong revenue growth with net sales up 38.90% year-on-year, but profitability declined significantly, with net profit down 39.89% and operating margins at their lowest in eight quarters. Overall, the results reflect good revenue performance but concerning profitability issues.

AstraZeneca Pharma India Ltd's latest results for Q3 FY26 present a mixed picture. On one hand, the company achieved impressive revenue growth, with net sales reaching ₹611.57 crores, marking a 9.39% increase quarter-on-quarter and a substantial 38.90% increase year-on-year. This indicates strong demand across its therapeutic portfolio and represents the seventh consecutive quarter of sequential revenue growth.<BR><BR>However, the profitability metrics are concerning. The net profit fell significantly by 39.89% quarter-on-quarter to ₹32.59 crores, despite the revenue increase. Additionally, the operating margin dropped sharply to 7.33%, the lowest level in eight quarters, down from 13.45% in the previous quarter. This margin compression is primarily attributed to a dramatic rise in employee costs, which surged by 55% quarter-on-quarter.<BR><BR>Overall, while the revenue growth is a positive sign, the significant decline in profitability and margins raises questions about the company's operational efficiency and cost management. Therefore, the results can be seen as bad in terms of profitability despite good revenue growth.

Should I buy, sell or hold Astrazeneca Pharma India Ltd?

Which are the latest news on Astrazeneca Phar?

Why is Astrazeneca Pharma India Ltd falling/rising?

As of 17-Mar, Astrazeneca Pharma India Ltd's stock price is rising to 8,445.30, indicating a potential shift in market sentiment after a trend reversal. This increase is supported by a significant rise in delivery volume, despite ongoing challenges such as declining quarterly profits and low cash reserves.

As of 17-Mar, Astrazeneca Pharma India Ltd's stock price is rising, currently at 8,445.30, with an increase of 87.1 (1.04%). This upward movement follows a trend reversal after four consecutive days of decline, indicating a potential shift in market sentiment. Additionally, the stock has outperformed its sector by 0.76% today, suggesting positive investor interest.<BR><BR>The rise in stock price is also supported by a significant increase in delivery volume, which rose by 130.22% compared to the 5-day average, indicating heightened investor participation. Despite the stock trading below its moving averages across various periods, the recent performance suggests a recovery phase.<BR><BR>However, it is important to note that the company has faced challenges, including a substantial decline in quarterly profits and low cash reserves. These factors contribute to a complex picture of the stock's performance, but the immediate rise can be attributed to the recent trend reversal and increased trading activity.

Why is Astrazeneca Pharma India Ltd falling/rising?

As of 18-Mar, Astrazeneca Pharma India Ltd's stock price is rising to 8,495.70, reflecting a 0.6% increase. Despite recent gains and strong annual performance, the stock has underperformed over the past month and faces valuation concerns.

As of 18-Mar, Astrazeneca Pharma India Ltd's stock price is rising, currently at 8,495.70, with a change of 50.4 (0.6%) upwards. This increase can be attributed to a few key factors. Firstly, the stock has outperformed its sector by 0.33% today and has shown a consecutive gain over the last two days, resulting in a total return of 1.65% during this period. <BR><BR>Despite this recent positive movement, it is important to note that the stock has been underperforming in the longer term, with a decline of 4.42% over the past month and 5.71% year-to-date. However, it has demonstrated strong performance over the past year, generating a return of 7.27%, which is significantly better than the BSE500 index. <BR><BR>The company also exhibits high management efficiency, reflected in a return on equity (ROE) of 21.62% and a low debt-to-equity ratio, indicating a stable financial position. Nevertheless, there are concerns regarding its valuation, as the stock is trading at a premium compared to its peers, with a price-to-book value of 26.6. <BR><BR>In summary, while Astrazeneca Pharma India Ltd is currently experiencing a rise in stock price due to recent gains and strong historical performance, it faces challenges such as declining investor participation and concerns over its valuation relative to earnings growth.

Why is Astrazeneca Pharma India Ltd falling/rising?

As of 19-Mar, Astrazeneca Pharma India Ltd's stock price is declining, currently at 8,348.45, down 1.73%. The stock is underperforming the market, trading below key moving averages, and facing concerns over financial health due to a significant drop in profit and high valuation metrics.

As of 19-Mar, Astrazeneca Pharma India Ltd's stock price is falling, currently at 8,348.45, reflecting a decrease of 147.25 points or 1.73%. This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed compared to the broader market, with a 1-week performance of -2.91% against the Sensex's -2.40%. Over the past month, the stock has decreased by 6.16%, while the Sensex has dropped by 10.05%. <BR><BR>Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Investor participation has also diminished, with delivery volume falling by 33.75% compared to the 5-day average. The Pharmaceuticals & Drugs sector has seen a decline of 2.13%, contributing to the stock's downward movement.<BR><BR>Financially, the company reported a significant drop in profit after tax (PAT) for the December quarter, falling by 45.6% compared to the previous four-quarter average. This, coupled with the lowest cash and cash equivalents recorded at Rs 399.94 crore and a low PBDIT of Rs 44.83 crore, raises concerns about the company's financial health. Furthermore, the stock is considered expensive with a price-to-book value of 26.1, which is above the average historical valuations of its peers, despite a return of 5.59% over the past year. These factors collectively explain the current decline in Astrazeneca Pharma India Ltd's stock price.

Why is Astrazeneca Pharma India Ltd falling/rising?

As of 20-Mar, Astrazeneca Pharma India Ltd's stock price is declining at 8,302.00, down -0.63%, and has underperformed its sector. The stock is trading below all key moving averages, with decreased investor participation and flat financial results contributing to a bearish outlook.

As of 20-Mar, Astrazeneca Pharma India Ltd's stock price is falling, currently at 8,302.00, reflecting a change of -52.45 (-0.63%). The stock has underperformed its sector by -2.33% today and has been on a consecutive decline for the last two days, resulting in a total drop of -2.28% during this period. <BR><BR>The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, there has been a significant decrease in investor participation, with delivery volume falling by -32.77% compared to the 5-day average. <BR><BR>Financial results have also contributed to the stock's decline, as the company reported flat results for the quarter ending December 25, with a profit after tax (PAT) of Rs 31.55 crore, which represents a -45.6% decrease compared to the previous four-quarter average. The company's cash and cash equivalents are at their lowest, recorded at Rs 399.94 crore, and the profit before depreciation, interest, and taxes (PBDIT) is also at a low of Rs 44.83 crore.<BR><BR>Furthermore, the stock is perceived as overvalued, trading at a price-to-book value of 26, which is considered expensive relative to its peers. Despite a modest return of -0.71% over the past year, the company's profits have increased by 16.3%, leading to a high PEG ratio of 6.1, which may deter investors. These factors collectively contribute to the downward pressure on Astrazeneca Pharma India Ltd's stock price.

Why is Astrazeneca Pharma India Ltd falling/rising?

As of 23-Mar, Astrazeneca Pharma India Ltd's stock price is declining, currently at 8,106.70, down 2.38% and trading below key moving averages. This trend is influenced by a significant drop in investor participation and concerning financial performance indicators, including a 45.6% decline in profit after tax.

As of 23-Mar, Astrazeneca Pharma India Ltd's stock price is falling, currently at 8,106.70, which reflects a decrease of 197.75 or 2.38%. The stock has been on a downward trend, having lost value for the last three consecutive days, with a total decline of 4.58% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend.<BR><BR>The broader market context shows that the Pharmaceuticals & Drugs sector has also experienced a decline of 3.58%, contributing to the negative sentiment surrounding the stock. Furthermore, investor participation appears to be decreasing, as evidenced by a significant drop in delivery volume, which fell by 38.9% compared to the 5-day average.<BR><BR>Financial performance indicators reveal concerning trends as well. The company's recent quarterly results showed a substantial decline in profit after tax (PAT), which fell by 45.6% compared to the previous four-quarter average. Additionally, cash and cash equivalents are at their lowest level, and the profit before depreciation, interest, and taxes (PBDIT) is also at a low point. Despite a high return on equity (ROE) of 21.62%, the stock is considered expensive with a price-to-book value of 25.4, which is above the average historical valuations of its peers. <BR><BR>Overall, these factors collectively contribute to the stock's current decline, reflecting both internal financial challenges and broader market pressures.

Why is Astrazeneca Pharma India Ltd falling/rising?

As of 24-Mar, Astrazeneca Pharma India Ltd's stock price is rising to 8,297.45, reflecting a 1.75% increase after a trend reversal and significant investor interest. Despite trading below moving averages, the stock shows signs of a rebound with heightened trading activity.

As of 24-Mar, Astrazeneca Pharma India Ltd's stock price is rising, currently at 8,297.45, reflecting an increase of 142.95 (1.75%). This upward movement can be attributed to several factors. Notably, the stock has shown a trend reversal, gaining after three consecutive days of decline. Additionally, it opened with a significant gap up of 3.01% today and reached an intraday high of Rs 8,399.95.<BR><BR>The stock has outperformed its sector by 0.63%, indicating a relative strength compared to its peers. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 298.95% against the 5-day average, suggesting heightened interest from investors.<BR><BR>Despite these positive indicators, the stock is trading below its moving averages across various time frames, which could indicate underlying weakness. However, the recent performance and increased trading activity suggest that the stock is currently experiencing a rebound, contributing to its rise in price.

Why is Astrazeneca Pharma India Ltd falling/rising?

As of 25-Mar, Astrazeneca Pharma India Ltd's stock price is rising, currently at 8,429.00, reflecting a change of 139.15 (1.68%) upward. The increase is driven by recent gains and strong historical performance, although there are concerns about declining investor participation and challenges in long-term outlook.

As of 25-Mar, Astrazeneca Pharma India Ltd's stock price is rising, currently at 8,429.00, reflecting a change of 139.15 (1.68%) upward. This increase can be attributed to a few key factors. The stock has been gaining for the last two days, with a total return of 3.37% during this period. Additionally, it reached an intraday high of Rs 8,589.85, which represents a 3.62% increase at its peak today.<BR><BR>Despite the recent positive movement, it is important to note that the stock has experienced a decline over longer periods, with a 4.44% drop over the past month and a year-to-date decrease of 6.45%. However, it has shown strong performance over the last three years, with a remarkable 150.43% increase compared to a 30.85% rise in the benchmark Sensex.<BR><BR>The stock's performance today is described as inline with the sector, but there are concerns regarding falling investor participation, as evidenced by a significant drop in delivery volume, which fell by 53.55% against the five-day average. Furthermore, while the company has high management efficiency with a return on equity (ROE) of 21.62% and a low debt-to-equity ratio, it faces challenges such as flat quarterly results and a high valuation compared to its peers.<BR><BR>In summary, Astrazeneca Pharma India Ltd's stock is currently rising due to recent gains and strong historical performance, despite underlying concerns that may affect its longer-term outlook.